Doxil receives FDA market clearance.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D018849:Controlled Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage*; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin